Tenax Therapeutics Reports Q4 Loss

Biopharmaceutical company beats Wall Street expectations despite $15.5 million loss

Published on Mar. 10, 2026

Got story updates? Submit your updates here. ›

Tenax Therapeutics Inc., a biopharmaceutical company based in Chapel Hill, North Carolina, reported a loss of $15.5 million in its fourth quarter. However, the company's results topped Wall Street expectations, with the average estimate of four analysts surveyed by Zacks Investment Research calling for a loss of $1.26 per share. For the full year, Tenax Therapeutics reported a loss of $52.6 million, or $1.34 per share.

Why it matters

Tenax Therapeutics is a publicly traded biopharmaceutical company focused on developing and commercializing products for the critical care market. The company's financial performance and ability to meet or exceed analyst expectations is closely watched by investors and industry observers as an indicator of the company's overall health and prospects.

The details

In the fourth quarter, Tenax Therapeutics reported a loss of $15.5 million, or 38 cents per share. This was better than the average analyst estimate of a $1.26 per share loss. For the full year, the company reported a loss of $52.6 million, or $1.34 per share.

  • Tenax Therapeutics reported its Q4 and full-year 2025 financial results on March 10, 2026.

The players

Tenax Therapeutics Inc.

A biopharmaceutical company based in Chapel Hill, North Carolina that is focused on developing and commercializing products for the critical care market.

Got photos? Submit your photos here. ›

The takeaway

Tenax Therapeutics' ability to exceed analyst expectations for its Q4 financial results, despite reporting an overall loss for the quarter and full year, suggests the company is making progress in its efforts to develop and commercialize its critical care products. Investors will be closely watching the company's future performance and pipeline developments.